Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized trial of LY3540378 in worsening HFpEF
jRCT2051220131Phase 2Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2023
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of volenrelaxin in heart failure with preserved ejection fraction (HFpEF) (4 arms), sponsored by Eli Lilly and Company. Primary endpoint: Change from baseline in left atrial reservoir strain (LARS). Started Jul 2023; status: active, not recruiting.
02
Drugs
volenrelaxin
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on jRCT2051220131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051220131.